Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results, surpassing the expectations of the researchers involved.

University of Oxford surgeons Prof Robert MacLaren and Mr Markus Groppe are currently running the retinal gene therapy trial at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Trust © Mr John Brett, Oxford Eye Hospital Photographic Department
University of Oxford surgeons Prof Robert MacLaren and Mr Markus Groppe are currently running the retinal gene therapy trial at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Trust

OxSTAR

Overview

Potential Projects

Global Anaesthesia Course

Global Anaesthesia Course (formerly known as Anaesthesia in Developing Countries (ADC)). Next course: 23 to 27 November 2026

Oxford Neurology Course

The Oxford Neurology Course is about much more than CME points. Active audience participation, refreshments with networking and a dinner, are all part of the memorable experience we want to offer our delegates. The 2026 course was held from the 1 to 3 July. Dates for 2027 to be confirmed.

Similar stories